Correlation of clinical parameters with risk groups in the training cohort (n = 351)
| Characteristic . | Low-risk, % . | High-risk, % . | P . |
|---|---|---|---|
| Age, 65 y or older | 20 | 20 | .856 |
| Albumin, less than 35 g/L | 13 | 35 | .001 |
| β2-microglobulin | |||
| Less than 297.5 nM | 62 | 42 | .005 |
| 297.5 nM or more to less than 467.5 nM | 20 | 20 | |
| 467.5 nM or more | 19 | 40 | |
| C-reactive protein, 4 mg/L or more | 51 | 62 | .235 |
| LDH, 190 IU/L or more | 30 | 59 | < .001 |
| Interphase FISH-defined del13 | 31 | 49 | .031 |
| Cytogenetic abnormalities | 26 | 70 | < .001 |
| GEP-based translocations | |||
| CCND1 | 20 | 0 | < .001 |
| MMSET | 12 | 28 | |
| MAF/MAFB | 3 | 9 | |
| No spike | 65 | 63 | |
| Characteristic . | Low-risk, % . | High-risk, % . | P . |
|---|---|---|---|
| Age, 65 y or older | 20 | 20 | .856 |
| Albumin, less than 35 g/L | 13 | 35 | .001 |
| β2-microglobulin | |||
| Less than 297.5 nM | 62 | 42 | .005 |
| 297.5 nM or more to less than 467.5 nM | 20 | 20 | |
| 467.5 nM or more | 19 | 40 | |
| C-reactive protein, 4 mg/L or more | 51 | 62 | .235 |
| LDH, 190 IU/L or more | 30 | 59 | < .001 |
| Interphase FISH-defined del13 | 31 | 49 | .031 |
| Cytogenetic abnormalities | 26 | 70 | < .001 |
| GEP-based translocations | |||
| CCND1 | 20 | 0 | < .001 |
| MMSET | 12 | 28 | |
| MAF/MAFB | 3 | 9 | |
| No spike | 65 | 63 | |